{
    "Trade/Device Name(s)": [
        "EliA PR3s Immunoassay",
        "EliA MPOs Immunoassay",
        "EliA GBM Immunoassay"
    ],
    "Submitter Information": "Phadia AB",
    "510(k) Number": "K173792",
    "Predicate Device Reference 510(k) Number(s)": [
        "K140225"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MOB",
        "MVJ"
    ],
    "Summary Letter Date": "December 12, 2017",
    "Summary Letter Received Date": "December 14, 2017",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.5660"
    ],
    "Regulation Name(s)": [
        "Multiple autoantibodies immunological test system"
    ],
    "Analyte Class(es)": [
        "autoimmune",
        "immunology"
    ],
    "Analyte(s)": [
        "Anti-PR3 autoantibodies",
        "Anti-MPO autoantibodies",
        "Anti-GBM autoantibodies"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Li-heparin tube",
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Phadia 2500",
        "Phadia 5000"
    ],
    "Method(s)/Technology(ies)": [
        "Semi-quantitative immunoassay",
        "Enzyme immunoassay",
        "Immunofluorescence measurement"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Control",
        "Calibrator",
        "Automated system"
    ],
    "Document Summary": "FDA 510(k) summary for EliA PR3s, MPOs, and GBM immunoassays using Phadia 2500/5000 for detection of autoantibodies related to GPA, MPA, and Goodpasture syndrome",
    "Indications for Use Summary": "Aids in clinical diagnosis of Granulomatosis with Polyangiitis, microscopic polyangiitis, and Goodpasture syndrome by measuring specific IgG autoantibodies in human serum and plasma, used in conjunction with other laboratory and clinical findings",
    "fda_folder": "Immunology"
}